JP2018502911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502911A5 JP2018502911A5 JP2017552008A JP2017552008A JP2018502911A5 JP 2018502911 A5 JP2018502911 A5 JP 2018502911A5 JP 2017552008 A JP2017552008 A JP 2017552008A JP 2017552008 A JP2017552008 A JP 2017552008A JP 2018502911 A5 JP2018502911 A5 JP 2018502911A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- formula
- compound
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 66
- 125000000217 alkyl group Chemical group 0.000 claims 61
- 229910052739 hydrogen Inorganic materials 0.000 claims 54
- 239000001257 hydrogen Substances 0.000 claims 54
- 150000002431 hydrogen Chemical class 0.000 claims 50
- 125000003118 aryl group Chemical group 0.000 claims 27
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 27
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 27
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims 26
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 26
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 25
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 24
- 125000001072 heteroaryl group Chemical group 0.000 claims 24
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 24
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 23
- 125000003710 aryl alkyl group Chemical group 0.000 claims 22
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 21
- 125000004404 heteroalkyl group Chemical group 0.000 claims 21
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 21
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- -1 R 18 Chemical compound 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 210000000056 organ Anatomy 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 102000004420 Creatine Kinase Human genes 0.000 claims 5
- 108010042126 Creatine kinase Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 4
- 208000016361 genetic disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 102100023153 Sodium- and chloride-dependent creatine transporter 1 Human genes 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 229960003624 creatine Drugs 0.000 claims 3
- 239000006046 creatine Substances 0.000 claims 3
- 108010007169 creatine transporter Proteins 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 238000003786 synthesis reaction Methods 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010049565 Muscle fatigue Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000003833 cell viability Effects 0.000 claims 2
- 230000019439 energy homeostasis Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000036542 oxidative stress Effects 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 125000005504 styryl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 0 CCC(*N(C1)C(N)=NC(*)(N)OC1=O)I Chemical compound CCC(*N(C1)C(N)=NC(*)(N)OC1=O)I 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095295P | 2014-12-22 | 2014-12-22 | |
| US62/095,295 | 2014-12-22 | ||
| PCT/US2015/067283 WO2016106284A2 (en) | 2014-12-22 | 2015-12-22 | Creatine prodrugs, compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072408A Division JP7037597B2 (ja) | 2014-12-22 | 2020-04-14 | クレアチンプロドラッグ、その組成物、及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502911A JP2018502911A (ja) | 2018-02-01 |
| JP2018502911A5 true JP2018502911A5 (https=) | 2018-12-13 |
| JP6692372B2 JP6692372B2 (ja) | 2020-05-13 |
Family
ID=56128653
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552008A Active JP6692372B2 (ja) | 2014-12-22 | 2015-12-22 | クレアチンプロドラッグ、その組成物、及びその使用方法 |
| JP2020072408A Active JP7037597B2 (ja) | 2014-12-22 | 2020-04-14 | クレアチンプロドラッグ、その組成物、及びその使用方法 |
| JP2022033882A Active JP7676338B2 (ja) | 2014-12-22 | 2022-03-04 | クレアチンプロドラッグ、その組成物、及びその使用方法 |
| JP2025075259A Pending JP2025118733A (ja) | 2014-12-22 | 2025-04-30 | クレアチンプロドラッグ、その組成物、及びその使用方法 |
| JP2025252487A Pending JP2026048846A (ja) | 2014-12-22 | 2025-12-16 | クレアチンプロドラッグ、その組成物、及びその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072408A Active JP7037597B2 (ja) | 2014-12-22 | 2020-04-14 | クレアチンプロドラッグ、その組成物、及びその使用方法 |
| JP2022033882A Active JP7676338B2 (ja) | 2014-12-22 | 2022-03-04 | クレアチンプロドラッグ、その組成物、及びその使用方法 |
| JP2025075259A Pending JP2025118733A (ja) | 2014-12-22 | 2025-04-30 | クレアチンプロドラッグ、その組成物、及びその使用方法 |
| JP2025252487A Pending JP2026048846A (ja) | 2014-12-22 | 2025-12-16 | クレアチンプロドラッグ、その組成物、及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9617230B2 (https=) |
| EP (2) | EP3771709B1 (https=) |
| JP (5) | JP6692372B2 (https=) |
| AR (2) | AR103254A1 (https=) |
| CA (1) | CA2971729C (https=) |
| ES (1) | ES2832333T3 (https=) |
| TW (3) | TWI700270B (https=) |
| WO (1) | WO2016106284A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9617230B2 (en) | 2014-12-22 | 2017-04-11 | Farmington Pharma Development | Creatine prodrugs, compositions and methods of use thereof |
| US11021501B2 (en) | 2015-03-30 | 2021-06-01 | Farmington Pharma Development | Creatine phosphate analog prodrugs, compositions and methods of use thereof |
| KR102678696B1 (ko) * | 2017-12-01 | 2024-06-27 | 울트라제닉스 파마수티컬 인코포레이티드 | 크레아틴 전구약물, 조성물과 이의 사용 방법 |
| CN110746325A (zh) * | 2018-07-24 | 2020-02-04 | 上海和辉光电有限公司 | 一种基于胍骨架的n型掺杂化合物及其应用 |
| CN114419050B (zh) * | 2022-03-31 | 2022-06-21 | 武汉大学 | 胃黏膜可视化程度量化方法、装置、终端及可读存储介质 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4767627A (en) | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4915952A (en) | 1987-02-27 | 1990-04-10 | Alza Corporation | Composition comprising drug, HPC, HPMC and PEO |
| US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
| US5002772A (en) | 1988-05-31 | 1991-03-26 | Pfizer Inc. | Gastric retention system for controlled drug release |
| CA1340821C (en) | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| EP0595894B1 (en) | 1991-07-19 | 1995-12-20 | UNIROYAL CHEMICAL COMPANY, Inc. | Seed film compositions |
| US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
| US5643909A (en) | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
| US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
| AU4151996A (en) | 1994-11-08 | 1996-05-31 | Avicena Group, Inc. | Use of creatine or creatine analogs for the treatment of diseases of the nervous system |
| US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
| MY113429A (en) | 1995-02-28 | 2002-02-28 | Univ Temple | Controlled release tablet containing swellable polyethylene oxide |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| AU721190B2 (en) | 1995-10-11 | 2000-06-29 | Avicena Group, Inc. | Use of creatine analogues for the treatment of disorders of glucose metabolism |
| US5783212A (en) | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
| IT1282650B1 (it) | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| US6008252A (en) * | 1996-07-26 | 1999-12-28 | Beale; Paxton K. | Method for increasing muscle mass in a mammal |
| US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
| GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| PT1003476E (pt) | 1997-08-11 | 2005-05-31 | Alza Corp | Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica |
| US6090411A (en) | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
| US6797283B1 (en) | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
| US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| US20030008007A1 (en) | 2001-04-23 | 2003-01-09 | Jose Gutierrez-Rocca | Release pharmaceutical construct for gastric retention |
| US20030013767A1 (en) | 2001-07-13 | 2003-01-16 | Samuel Bessman | Method of treating weight loss using creatine |
| US20040219186A1 (en) | 2001-08-16 | 2004-11-04 | Ayres James W. | Expandable gastric retention device |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| AU2002363998A1 (en) | 2001-12-15 | 2003-06-30 | Spherics, Inc. | Bioadhesive drug delivery system with enhanced gastric retention |
| EP1478345A4 (en) | 2002-01-03 | 2010-11-17 | Glaxosmithkline Llc | NOVEL PHARMACEUTICAL DOSAGE FORMS AND PROCESS FOR PRODUCTION OF SAID DOSAGE FORMS |
| DE10221344A1 (de) | 2002-05-14 | 2003-12-04 | Hannover Med Hochschule | Transgene Ratte und ihre Verwendung im Tiermodell für die humane Chorea Huntington Erkrankung sowie Nukleinsäurekonstrukte, Vektoren und Zellen zu ihrer Erzeugung |
| BR0310100A (pt) | 2002-05-17 | 2007-04-27 | Esperion Therapeutics Inc | métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto |
| US20040102525A1 (en) | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
| GB0214013D0 (en) | 2002-06-18 | 2002-07-31 | Euro Celtique Sa | Pharmaceutical product |
| WO2004002445A2 (en) | 2002-06-26 | 2004-01-08 | Cadila Healthcare Limited | Novel floating dosage form |
| US20040120983A1 (en) * | 2002-12-23 | 2004-06-24 | Philip Connolly | Nutritional supplement |
| JPWO2005108370A1 (ja) * | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| US20070012105A1 (en) | 2005-07-13 | 2007-01-18 | Barnes-Jewish Hospital | Method and apparatus for resistive characteristic assessment |
| US20070032750A1 (en) | 2005-07-15 | 2007-02-08 | Jeffrey Oster | Muscle strength assessment system |
| US7683043B2 (en) | 2006-06-06 | 2010-03-23 | Xenoport, Inc. | Creatine phosphate analog prodrugs, compositions and uses thereof |
| WO2007146085A2 (en) | 2006-06-06 | 2007-12-21 | Xenoport, Inc. | Creatine phosphate prodrugs, compositions and uses thereof |
| US20070281995A1 (en) * | 2006-06-06 | 2007-12-06 | Xenoport, Inc. | Creatine analog prodrugs, compositions and uses thereof |
| WO2008101310A1 (en) * | 2007-02-20 | 2008-08-28 | Multi Formulations Ltd. | Creatine-fatty acids |
| US7319157B1 (en) | 2007-02-20 | 2008-01-15 | Multi Formulations Ltd. | Creatine-fatty acids |
| US8426395B2 (en) | 2008-05-30 | 2013-04-23 | Northern Northern Innovations Holding Corp | Preparations containing creatine and imino sugars |
| WO2010005692A2 (en) | 2008-06-16 | 2010-01-14 | E. I. Du Pont De Nemours And Company | Insecticidal cyclic carbonyl amidines |
| HK1200459A1 (en) * | 2011-09-19 | 2015-08-07 | Gencia Corporation | Modified creatine compounds |
| US9233099B2 (en) | 2012-01-11 | 2016-01-12 | University Of Cincinnati | Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| AR091857A1 (es) | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
| EP2692719B1 (en) * | 2012-07-30 | 2016-06-08 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof |
| ITTO20121098A1 (it) * | 2012-12-18 | 2014-06-19 | Univ Degli Studi Genova | Procedimento per sintetizzare derivati della creatina |
| US20160289175A1 (en) * | 2013-11-05 | 2016-10-06 | Ultragenyx Pharmaceutical Inc. | Creatine analogs and the use thereof |
| ITTO20131070A1 (it) * | 2013-12-24 | 2015-06-25 | Univ Degli Studi Genova | Applicazione terapeutica di un derivato di creatina |
| US9617230B2 (en) | 2014-12-22 | 2017-04-11 | Farmington Pharma Development | Creatine prodrugs, compositions and methods of use thereof |
| WO2016110822A1 (en) * | 2015-01-09 | 2016-07-14 | Universita' Degli Studi Di Genova | Carboxylic biacyl creatine derivative, uses and method of synthesis thereof |
| US11021501B2 (en) | 2015-03-30 | 2021-06-01 | Farmington Pharma Development | Creatine phosphate analog prodrugs, compositions and methods of use thereof |
-
2015
- 2015-12-21 US US14/975,950 patent/US9617230B2/en active Active
- 2015-12-22 EP EP20184803.3A patent/EP3771709B1/en active Active
- 2015-12-22 EP EP15874283.3A patent/EP3237391B1/en active Active
- 2015-12-22 WO PCT/US2015/067283 patent/WO2016106284A2/en not_active Ceased
- 2015-12-22 CA CA2971729A patent/CA2971729C/en active Active
- 2015-12-22 TW TW104143162A patent/TWI700270B/zh active
- 2015-12-22 JP JP2017552008A patent/JP6692372B2/ja active Active
- 2015-12-22 TW TW111136599A patent/TWI832450B/zh active
- 2015-12-22 TW TW109123072A patent/TWI779312B/zh active
- 2015-12-22 ES ES15874283T patent/ES2832333T3/es active Active
- 2015-12-22 AR ARP150104265A patent/AR103254A1/es active IP Right Grant
-
2017
- 2017-04-07 US US15/481,568 patent/US10344007B2/en active Active
-
2019
- 2019-05-22 US US16/419,596 patent/US11407722B2/en active Active
-
2020
- 2020-04-14 JP JP2020072408A patent/JP7037597B2/ja active Active
-
2021
- 2021-05-14 AR ARP210101331A patent/AR122096A2/es unknown
-
2022
- 2022-03-04 JP JP2022033882A patent/JP7676338B2/ja active Active
-
2025
- 2025-04-30 JP JP2025075259A patent/JP2025118733A/ja active Pending
- 2025-12-16 JP JP2025252487A patent/JP2026048846A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502911A5 (https=) | ||
| AU2018358157B2 (en) | Modulators of the integrated stress pathway | |
| RU2435759C2 (ru) | Производные бензимидазолов и их применение для модуляции гамка-рецепторного комплекса | |
| CA3138182A1 (en) | Substituted cycloalkyls as modulators of the integrated stress pathway | |
| JP2020502049A5 (https=) | ||
| AU2018360855A1 (en) | Modulators of the integrated stress pathway | |
| AU2018360854A1 (en) | Modulators of the integrated stress pathway | |
| JP2011509309A5 (https=) | ||
| CA3080968A1 (en) | Modulators of the integrated stress pathway | |
| CA3080959A1 (en) | Modulators of the integrated stress pathway | |
| JP2005509632A5 (https=) | ||
| TW200901978A (en) | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenyl-imidazolone compounds for the inhibition of β-secretase | |
| JP6595078B2 (ja) | アミノカルボニルカルバメート化合物 | |
| JP2019519593A5 (https=) | ||
| JP2017511378A5 (https=) | ||
| JP2007500177A5 (https=) | ||
| JP2009543799A5 (https=) | ||
| WO2012039460A1 (ja) | 置換アミド化合物 | |
| JP2006501201A5 (https=) | ||
| JP2004528385A5 (https=) | ||
| JP2007500222A5 (https=) | ||
| JP2004525183A5 (https=) | ||
| JP2019525900A5 (https=) | ||
| RU2008119994A (ru) | Ингибиторы калиевых каналов | |
| JP7416757B2 (ja) | 置換テトラヒドロシクロペンタ［ｃ］ピロール、置換ジヒドロピロリジン、その類似体、およびそれらを使用する方法 |